[December 06, 2012] |
|
US Oncology Research Affiliated Investigators Participate in Studies That Will Be Presented at the 2012 American Society of Hematology Annual Meeting and Exposition
THE WOODLANDS, Texas --(Business Wire)--
Eleven leading investigators affiliated with US
Oncology Research participated in nearly 20 studies that will be
presented at the 54th American Society of Hematology (ASH)
Annual Meeting and Exposition in Atlanta, Ga. at the Georgia World
Congress Center. ASH will take place Dec. 8-11 and is an educational and
scientific program that helps Hematology professionals stay up-to-date
on the latest research, therapies, and tools needed to be successful in
their field.
John
Burke, M.D., medical oncologist and hematologist with Rocky
Mountain Cancer Centers, an affiliate of US Oncology Research, is
presenting a study titled, "Differences
in Quality of Life Between Bendamustine Plus Rituximab Compared with
Standard First-Line Treatments in Patients with Previously Untreated
Advanced Indolent Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma,"
on Dec. 9 at 5:30pm. This study compared the efficacy and safety of the
combination of bendamustine and rituximab with standard therapy in the
first-line treatment of patients with indolent non-Hodgkin's lymphoma or
mantle cell lymphoma. Kathryn
Kolibaba, M.D., medical oncologist and hematologist with Compass
Oncology, an affiliate of US Oncology Research, also participated in
this study.
In addition to Dr. Burke's presentation, 18 other US Oncology Research
affiliated studies will be featured as oral presentations, posters or
publications at this year's meeting. Affiliated physicians Robert
Rifkin, M.D., hematologist with Rocky Mountain Cancer Centers, as
well as Hakan
Kaya, M.D., medical oncologist and hematologist with Cancer
Care Northwest, will also participate in Case Discussions on Dec. 7.
A full list of US Oncology Research affiliated studies on display at the
ASH Annual Meeting is below. For more information or to interview an
investigator, contact US Oncology Research Public Relations Manager,
Claire Crye at 281-863-6783.
Oral Presentations:
-
Efficacy, Hematologic Effects, and Dose of Ruxolitinib in
Myelofibrosis Patients with Low Starting Platelet Counts (50-100 x 109/L):
A Comparison to Patients with Normal or HighStarting Platelet Counts
Talpaz
M, Solomon H, Jamieson K, Lyons R, Winton E, Odenike T,
Kantarjian H, Verstovsek
-
The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI (News - Alert)-32765)
Promotes High Response Rate, Durable Remissions, and Is Tolerable in
Treatment Naïve (TN) and Relapsed or Refractory (RR) Chronic
Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Patients Including Patients with High-Risk (HR) Disease: New and
Updated Results of 116 Patients in a Phase Ib/II Study
Byrd
JC, Furman RR, Coutre S, Flinn IW, Burger JA, Blum KA, Sharman JP,
Grant B, Jones JA, Wierda WG, Zhao W, Heerema NA, Johnson AJ, Tran A,
Clow F, Kunkel L, James DF, O'Brien S
-
Differences in Quality of Life Between Bendamustine Plus Rituximab
Compared with Standard First-Line Treatments in Patients with
Previously Untreated Advanced Indolent Non-Hodgkin's Lymphoma or
Mantle Cell Lymphoma
Burke JM, Van der Jagt RH, Kahl
BS, Wood P, Hawkins TE, MacDonald D, Hertzberg M, Kwan Y-L, Simpson D,
Craig M, Kolibaba K, Issa S, White RE, Munteanu MC, Clementi R,
Chen L, Flinn IW
-
Combinations of the Selective Phosphatidylinositol 3-Kinase-Delta
(PI3Kdelta) Inhibitor GS-1101 (CAL-101) with Rituximab and/or
Bendamustine Are Tolerable and Highly Active in Patients with Relapsed
or Refractory Chronic Lymphocytic Leukemia (CLL): Results From a Phase
I Study
Coutre SE, Leonard JP, Furman rr, Barrientos JC, de
Vos s, Flinn IW, Schreeder MT, Wagner-Johnston ND, Sharman JP, Boyd
TE, Fowler NH, Holes LM, Lannutti BJ, Johnson DM, Miller LL, Jahn
TM
-
The Bruton's Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Is
Active and Tolerated in Relapsed Follicular Lymphoma
Fowler
NH, Advani RH, Sharman JP, Smith SM, McGreivy J, Kunkel L,
Troung V, Zhou C, Boyd TE
-
Ibrutinib Is an Irreversible Molecular Inhibitor of Interleukin-2
Inducible Kinase: Expanding Therapeutic Potential and Modulating a Th1
Selective Pressure in CD4 T-Cells
Dubovsky JA, Beckwith KA,
Woyach JA, Jaglowski SM, Hessler J, Chang BY, Larkin K,
Stefanovski MR, Frissora FW, SmitH LL, Smucker KA, Flynn JM, Jones JA,
Andritsos LA, Maddocks K, Lehman A, Furman RR, Sharman JP,
Mishra A, Caligiuri MA, Buggy JJ, Muthusamy N, Johnson AJ, Byrd JC
-
Long-Term Outcome of Ruxolitinib Treatment in Patients with
Myelofibrosis: Durable Reductions in Spleen Volume, Improvements in
Quality of Life, and Overall Survival Advantage in COMFORT-I
Verstovsek
S, Ruben M, Gotlib JR, Gupta V, Catalano J, Deininger M, Miller C,
Talpaz M, Winton E, Harvery J, Hexner E, Lyons R, Raza A,
Kantarjian H
-
An Open-Label, Randomized Study of Bendamustine and Rituximab (BR)
Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone
(R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and
Prednisone (R-CHOP) in First-Line Treatment of Patients with Advanced
Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL (News - Alert)):
The Bright Study
Flinn IW, Van der Jagt RH, Kahl BS,
Wood P, Hawkins TE, MacDonald D, Hertzberg M, Kwan Y-L, Simpson D,
Craig M, Kolibaba K, Issa S, Munteanu MC, Clementi R, Chen L, Burke
JM
Posters:
-
Phase 1b Study of TRU-016, an Anti-CD37 SMIPTM
Protein, in Combination with Bendamustine Vs Bendamustine Alone in
Relapsed Chronic Lymphocytic Leukemia
Awan F, Jaeger
U, Rifkin R, Thirman MJ, Byrd JC, Hallek M, Stromatt S, Pagel JM
-
Integrated Analysis of Long-Term Safety in Patients with Chronic
Immune Thrombocytopenia Treated with Romiplostim
Cines D,
Gernsheimer T, Wasser J, Godeau B, Provan D,
Lyons R, Altomare I, Wang X, Woodard P
-
Combinations of the Phosphatidylinositol 3-Kinase-Delta (PI3Kd)
Inhibitor Gs-1101 (CAL-101) with Rituximab and/or Bendamustine Are
Tolerable and Highly Active in Previously Treated, Indolent
Non-Hodgkin Lymphoma: Results From a Phase I Study
Fowler NH,
de Vos S, Schreeder MT, Leonard JP, Flinn IW, Coutre S,
Wagner-Johnston ND, Sharman JP, Boccia RV, Barrientos JC, Boyd
TE, Holes LM, Lannutti BJ, Johnson D, Jahn TM, Miller LL, Godfrey
WR
-
Results of a Phase 1 Dose-Escalation Study of Once-Weekly MLN9708,
an Investigational Proteasome Inhibitor, in Patients with
Relapsed/Refractory Lymphoma
Assouline S, Chang JE, Cheson
BD, Rifkin R, Hamburg S, Reyes R, Hui A-M, Yu J, Gupta N, Di
Bacco A, Shou Y, Martin P
-
Variation in Health-Related Quality of Life by Line of Therapy of
Patients with Chronic Lymphocytic Leukemia
Kay NE, Flowers
CR, Weiss M, Lamanna N, Flinn IW, Grinblatt D, Kipps TJ, Kozloff M,
Lerner S, Sharman JP, Yu R, Khan ZM, Street TK, Swern RS,
Sullivan KA, Pashos CL
-
A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or
Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results
Jacobsen
ED, Advani RH, Oki Y, Sharman JP, Horwitz SM, Forero-Torres A,
O'Connor OA, Shustov AR, Siddiqi T, Grove LE, Bartlett NL
-
Relationship between chelation and clinical outcomes in 600
lower-risk MDS patients: registry analysis at 36 months
Lyons
RM, Marek BJ, Paley C, Esposito J, Garbo L, Di Bella N,
Garcia-Manero G
-
Phase 2 trial of Intracycle Sequential Ofatumumab and Lenalidomide
for the Treatment of Relapsed and Refractory Chronic Lymphocytic
Leukemia
Costa LJ, Fanning SR, Stephenson JJ, Afrin
LB, Stuart RK, Bentz TA, Salzer S, Whirley R, Sanders C
Publication only:
-
Treatment with the Thrombopoietin Receptor (TPO-R) Agonist
Eltrombopag in Thrombocytopenic Patients (Pts) with Advances
Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) -
Results of a Placebo-Controlled, Randomized Phase I/III Trial
Platzbecker
U, Wong R, Verma A, Abboud C, Araujo S, Chiou T-J, Feigert J, Yeh
S-P, Götze K, Gorin N-C, Greenberg P, Kambhampati S, Kim Y-J, Lee J-H, Lyons
R, Ruggeri M, Santini V, Cheng G, Jang JH, Dougherty D, Mannino F,
Mostafa Kamel Y, Chan G, Arning M, Stone N, Giagounidis A
-
Oral Ezatiostat HCI (Telintra), a Glutathione Analog Prodrug
GSTP1-1 Inhibitor, for Treatment of Patients with Myeloid Growth
Factor-Resistant Idiopathic Chronic Neutropenia (ICN)
Lyons
R
-
Multiple Myeloma Care in the Community Setting by Utilizing
Progressive Clinical Care Pathways
Dhillon V, Martincic D,
Lee CM, Njuguna N, Schmick D, Nagle AK, Garman RL, Kaya H
Many clinical studies led by US Oncology Research affiliated physicians
have been prominently featured at numerous conferences held around the
world, including the annual congress for the European Society for
Medical Oncology (ESMO),
the annual meeting for the American Society for Clinical Oncology (ASCO)
and the San Antonio Breast Cancer Symposium (SABCS).
Those studies, along with 75 published investigator-initiated
manuscripts, feature forward looking clinical research topics that are
helping advance cancer care today and discover improved therapies for
the cancer care of tomorrow.
Names in bold are affiliated with US Oncology Research
About US Oncology Research
Supported by McKesson
Specialty Health and The
US Oncology Network, US Oncology Research draws from a network of
experienced investigators and dedicated clinical staff who specialize in
Phase I through Phase IV oncology clinical trials. US Oncology Research
serves more than 85 practices in nearly 250 locations managing more than
225 active trials at any given time. Physicians in the research network
have enrolled more than 53,000 patients in over 1,200 trials since
inception in 1992 and have contributed to the development of 43 cancer
therapies approved by the FDA. For more information call (800) 482-6700,
option 4 or visit www.usoncology.com/oncologists.
[ Back To TMCnet.com's Homepage ]
|